Literature DB >> 17012530

Selective processing of gastrointestinal symptom-related stimuli in irritable bowel syndrome.

Muhammad Afzal1, John P Potokar, Christopher S J Probert, Marcus R Munafò.   

Abstract

OBJECTIVES: We sought to determine whether irritable bowel syndrome (IBS) was associated with attentional bias toward symptom-related cues in IBS patients versus healthy controls, using a modified Stroop task to measure selective processing of gastrointestinal symptom-related cues.
METHODS: Fifteen patients with a clinical diagnosis of IBS and 15 healthy controls were recruited into the study. All participants attended a single testing session, during which they completed a modified Stroop task using gastrointestinal symptom-related and neutral control words.
RESULTS: Results indicated a significant main effect of word type (p = .013), with slower color-naming times for IBS-related compared with neutral words, and a significant main effect of exposure (p = .001), with slower color-naming times in the unmasked condition compared with the masked condition. The group x word type x exposure interaction was significant (p = .048). A series of post hoc tests indicated that among patients there was significant interference of symptom-related words in the masked condition but not in the unmasked condition, whereas among controls, the reverse was true.
CONCLUSIONS: These results indicate that IBS patients selectively process gastrointestinal symptom-related words compared with neutral words when they are presented subliminally but not when they are presented supraliminally. In contrast, healthy controls demonstrate the opposite pattern. Implications for the cognitive mechanisms in IBS, and future research directions, are discussed.

Entities:  

Mesh:

Year:  2006        PMID: 17012530     DOI: 10.1097/01.psy.0000232270.78071.28

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  8 in total

Review 1.  Developmental influences on medically unexplained symptoms.

Authors:  C A Tony Buffington
Journal:  Psychother Psychosom       Date:  2009-03-09       Impact factor: 17.659

Review 2.  Irritable bowel syndrome: a microbiome-gut-brain axis disorder?

Authors:  Paul J Kennedy; John F Cryan; Timothy G Dinan; Gerard Clarke
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  Increased attentional network functioning related to symptom severity measures in females with irritable bowel syndrome.

Authors:  C S Hubbard; J Hong; Z Jiang; B Ebrat; B Suyenobu; S Smith; N Heendeniya; B D Naliboff; K Tillisch; E A Mayer; J S Labus
Journal:  Neurogastroenterol Motil       Date:  2015-06-19       Impact factor: 3.598

Review 4.  Towards a systems view of IBS.

Authors:  Emeran A Mayer; Jennifer S Labus; Kirsten Tillisch; Steven W Cole; Pierre Baldi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-08-25       Impact factor: 46.802

Review 5.  Cognitive behavioral approach to understanding irritable bowel syndrome.

Authors:  Goran Hauser; Sanda Pletikosic; Mladenka Tkalcic
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 6.  Role of brain imaging in disorders of brain-gut interaction: a Rome Working Team Report.

Authors:  Emeran A Mayer; Jennifer Labus; Qasim Aziz; Irene Tracey; Lisa Kilpatrick; Sigrid Elsenbruch; Petra Schweinhardt; Lukas Van Oudenhove; David Borsook
Journal:  Gut       Date:  2019-06-07       Impact factor: 23.059

7.  Cognitive performance in irritable bowel syndrome: evidence of a stress-related impairment in visuospatial memory.

Authors:  P J Kennedy; G Clarke; A O'Neill; J A Groeger; E M M Quigley; F Shanahan; J F Cryan; T G Dinan
Journal:  Psychol Med       Date:  2013-08-29       Impact factor: 7.723

8.  Sex Differences Linking Pain-Related Fear and Interoceptive Hypervigilance: Attentional Biases to Conditioned Threat and Safety Signals in a Visceral Pain Model.

Authors:  Franziska Labrenz; Sopiko Knuf-Rtveliashvili; Sigrid Elsenbruch
Journal:  Front Psychiatry       Date:  2020-03-24       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.